---
title: Review Workflow Design for Validation Documents
date: 2026-10-23
description: How to design a review workflow for GxP validation documents: roles, risk-based routing, e-signatures, audit trail review and exception handling that holds up.
author: Qualitum
cover: https://media.babylovegrowth.ai/blog-images/organization-48457/1792577081473_Reviewers-compare-a-validation-protocol-with-equipment.jpeg
coverAlt: Reviewers compare a validation protocol with equipment
---

A good review workflow for validation documents does four things. It routes each document to the people who add distinct value, it makes the risk behind each decision visible, it captures every action in a record that cannot be quietly altered, and it ends in a signature that means something. Everything else, including software, templates and notification rules, is built on those four.

Most generic guidance on this topic is written for creative teams and design agencies. In a regulated life sciences setting the stakes differ. A URS, protocol or summary report is evidence that a system is fit for its intended use, and a reviewer's signature is a statement an inspector may read years later. This guide covers how to design that workflow so it is fast enough to keep up with your validation cycle and defensible enough to survive an inspection.

## TL;DR

- Route reviews by risk and decision needed, not by a standing list of everyone who might have an opinion.
- Give each reviewer a defined domain (technical accuracy, quality compliance, system ownership) so reviews do not overlap and nobody holds an unofficial veto.
- Treat the audit trail as part of the workflow: keep it enabled, review it on a risk basis, and use exception reporting rather than line-by-line reading.
- Keep humans as the authority. Automation can draft, check and route, but the signature belongs to a named person.
- Design the workflow for change, because validated systems are maintained through controlled change, not one-time document releases.

## Table of Contents

- [What a validation review workflow has to prove](#what-a-validation-review-workflow-has-to-prove)
- [Start with the documents and the decisions](#start-with-the-documents-and-the-decisions)
- [Route by risk, not by headcount](#route-by-risk-not-by-headcount)
- [Design the stages](#design-the-stages)
- [Build the audit trail into the workflow](#build-the-audit-trail-into-the-workflow)
- [Review the audit trail by exception](#review-the-audit-trail-by-exception)
- [Test the workflow like any other system](#test-the-workflow-like-any-other-system)
- [Design for change, not for a one-time release](#design-for-change-not-for-a-one-time-release)
- [Common design mistakes](#common-design-mistakes)
- [Our perspective: where agents fit and where they do not](#our-perspective-where-agents-fit-and-where-they-do-not)
- [Where Qualitum fits](#where-qualitum-fits)
- [A starting checklist](#a-starting-checklist)
- [FAQ](#faq)
- [Sources](#sources)

## What a validation review workflow has to prove

A review workflow in a GxP environment is a control, not a convenience. It has to show who reviewed what, when, against which version, and with what outcome. If any of those four is unclear, the review is hard to defend.

The regulatory frame is fairly consistent across jurisdictions. The FDA's guidance on [computer software assurance](https://www.fda.gov/media/188844/download) describes a risk-based approach to establishing confidence that software is fit for its intended use, and expects documentation to capture the intended use, the risk analysis, a description of testing and a clear conclusion of acceptability. Your review steps are where each of those elements gets checked by a second pair of eyes.

For signatures, [21 CFR Part 11 requirements](https://envigilance.com/compliance/21-cfr-part-11/) include that a signed electronic record shows the signer's printed name, the date and time of signing, and the meaning of the signature, such as review, approval or authorship. That has a direct design consequence: your workflow must distinguish between those meanings. A single generic "approve" button does not.

For a deeper look at how the lifecycle fits together, our guides on [GAMP 5 validation](https://blog.qualitum.ai/gamp-5-validation) and the [risk-based approach to computerized system validation](https://blog.qualitum.ai/gamp-5-risk-based) cover the surrounding framework.

![What a validation review workflow has to prove — overview diagram](https://media.babylovegrowth.ai/blog-images/organization-48457/1792577271606_What-a-validation-review-workflow-has-to-prove-overview-diagram.jpeg)

## Start with the documents and the decisions

Before drawing a single swimlane, list the documents that move through review and the decision each one supports. A typical set looks like this:

| Document | Decision it supports | Core reviewers |
|---|---|---|
| URS | Are the needs complete, testable and unambiguous? | System owner, process owner, QA |
| Risk assessment | Is the testing effort proportionate to risk? | System owner, QA, subject matter expert |
| FS / DQ | Does the design meet the requirements? | Technical lead, QA |
| IQ / OQ / PQ protocols | Will these tests prove fitness for use? | Validation, system owner, QA |
| Executed protocols | Did results meet acceptance criteria, and were deviations handled? | Validation, QA |
| Summary report | Is the system released for use? | System owner, QA |

The point of the table is that each document answers a different question. A reviewer who is not qualified to answer that question should not be on the route. This sounds obvious, yet many review lists are inherited from a template written years ago and never questioned.

## Route by risk, not by headcount

The most common design failure is the exhaustive reviewer list. Every stakeholder is added "just in case", every one can reject, and the document circulates for weeks. Guidance on content approval makes the same point outside life sciences: [approval should be routed by the decision needed](https://apaya.com/blog/content-approval-workflow), with defined review domains so that reviewers add specific, non-overlapping value, rather than committees where everyone can veto.

In validation, translate that into three practical rules.

1. **Tier your documents.** A high-risk system that affects product quality or data integrity gets the full route, including QA approval and system owner sign-off. A low-risk, configurable tool with no GxP impact may need a lighter route. This follows the logic of the risk-based thinking in the FDA's CSA guidance, which asks for assurance effort that is proportionate to the risk of compromised safety or quality.
2. **Define each reviewer's domain in writing.** The technical reviewer confirms the design and test logic. The system owner confirms that requirements reflect the real process. QA confirms compliance with procedures and regulations. Comments outside a reviewer's domain are advisory, not blocking.
3. **Separate review from approval.** Reviewers comment, authors resolve, approvers sign. Mixing these roles is how documents end up approved by someone who also wrote them.

### Sequential or parallel?

Parallel review is faster and suits independent domains, such as a technical review and a QA review running side by side. Sequential review suits dependencies, for instance when QA should only see a protocol after technical accuracy is confirmed, or when a final approver should see the consolidated comment history. Workflow tools commonly offer both patterns. General-purpose automation platforms, for example, document options such as [sequential approval and "everyone must approve"](https://learn.microsoft.com/en-us/power-automate/get-started-approvals), and your design decision is which pattern fits which document, not which button is available.

A reasonable default: parallel for the review stage, sequential for the approval stage.

## Design the stages

A workable validation review has five stages. Keep them identical across document types so that people learn one process.

### 1. Draft and self-check

The author confirms the document against the template, checks that every requirement has an identifier, and that references resolve. Errors caught here never reach reviewers, which is where most cycle time is wasted. Teams using agent-assisted authoring can have each draft re-checked automatically before it enters the route.

### 2. Technical and domain review

Reviewers work against a short checklist tied to their domain. For a protocol, that means: are test steps unambiguous, do expected results match the requirement, and are acceptance criteria measurable? Comments are logged against the specific version, and every comment gets a recorded disposition.

### 3. Quality review

QA reviews for compliance with the validation plan, applicable procedures and regulations, and for completeness of the evidence package. This is also where traceability is confirmed. A static traceability spreadsheet inevitably drifts, which is why current practice favors [generating traceability on demand from the system repository](https://sakaradigital.com/blog/analytics-engineering-regulated-environments-dbt-validation/), with each test case linked to a unique requirement identifier.

### 4. Approval and signature

Approvers sign with the meaning made explicit: authored, reviewed, approved. The signed record must show name, date and time, and meaning. Human signatures stay authoritative, whatever automation produced the draft.

### 5. Release and change

Approval is not the end. Documents enter controlled change management from the moment they are effective. More on that below.

## Build the audit trail into the workflow

The workflow itself generates records that regulators will examine. [MHRA's GxP data integrity guidance](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/687246/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf) treats secure, time-stamped audit trails as central to data integrity, and review of those trails is expected to be documented and focused on GMP-relevant actions such as creation, modification or deletion. A system in which the audit trail can be switched off is a serious data integrity concern.

For workflow design, that means:

- **Capture at write-time.** Each action (comment, edit, status change, signature) is recorded as it happens, attributable to a person, with a timestamp and the version it applied to.
- **Prevent silent edits.** Once a document is in review, changes create a new version and restart the affected review steps.
- **Record the reason for change.** A resolved comment should point to what changed and why.
- **Check the ALCOA+ attributes automatically.** Attributable, legible, contemporaneous, original, accurate, plus complete, consistent, enduring and available. The [ALCOA+ overview for clinical trials](https://gcpblog.org/alcoa-and-alcoa-data-integrity-in-clinical-trials/) frames these as questions about whether activities are documented at the time of performance and whether only authorized individuals can make changes. Our note on [write-time ALCOA+ and five audit fields](https://blog.qualitum.ai/write-time-alcoa) lists what validation teams should test.

## Review the audit trail by exception

Designing a workflow that produces rich audit trails creates a second problem: someone has to review them. Reading logs line by line is slow and, more importantly, rarely catches what matters.

The MHRA guidance points toward [exception reporting using validated search tools](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/687246/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf) to identify abnormal data or actions, so reviewers can concentrate on high-risk events while keeping oversight of the whole system. Practical exception filters for a validation workflow include:

- Approvals executed before the last review step closed.
- Edits to a document after signature.
- A signer approving a document they authored.
- Review durations far outside the norm, which can signal rubber-stamping.
- Deleted or reassigned review tasks.

Audit trail review should also be a routine activity, not an end-of-project chore. In clinical systems, guidance recommends [focusing on critical data changes](https://meddeviceguide.com/blog/edc-validation-medical-device-clinical-trials-part-11-audit-trail-data-integrity-guide) rather than trivial metadata such as log-on times, and the same principle applies to a validation repository: look at what changed in requirements, acceptance criteria and results. Our article on [audit-first review by exception](https://blog.qualitum.ai/review-by-exception) goes into packet design.

## Test the workflow like any other system

If your review workflow runs in software, it is itself a computerized system, and it needs validation proportionate to its risk. Two tests are worth singling out.

First, test the controls, not only the happy path. Try to approve out of sequence, sign without the right role, edit a locked version, and disable logging. Practitioners describe [negative testing](https://sakaradigital.com/blog/analytics-engineering-regulated-environments-dbt-validation/) as the most convincing way to show an auditor that validation is more than a performance: a test suite that has only ever passed is unexamined. Record the attempted failure and the system's response.

Second, verify that electronic records and signatures remain intact in the configured environment. Where teams build approvals on general business automation tools, the documentation notes that such flows need a managed environment to preserve record integrity, so confirm where approval records live and who can change the flow definition.

## Design for change, not for a one-time release

Older validation thinking treated documents as static packages released at the end of a linear project. Current GAMP 5 interpretation is more flexible. Iterative and incremental approaches are acceptable, provided the [validated state is maintained through controlled change management](https://sakaradigital.com/blog/analytics-engineering-regulated-environments-dbt-validation/). A [GAMP 5 summary](https://powerfabric.org/standards/gamp-5) makes the same point: validation is a controlled lifecycle, with evidence that traces from user needs through design, testing and release to ongoing state of control.

Your review workflow should therefore handle three paths:

- **New document:** the full route for its risk tier.
- **Revision:** a route that scopes review to what changed, with impact assessment attached. Reviewers see the delta and the affected requirements, not a 200-page document from scratch.
- **Periodic review:** a scheduled path confirming that the system remains in its validated state, triggering revalidation when needed.

For the change-control side, see our six-step guide to [inspector-ready validation change control](https://blog.qualitum.ai/validation-change-control), and for the document side, the [30, 90 and 180 day document control plan](https://blog.qualitum.ai/gxp-document-control).

## Common design mistakes

| Mistake | Why it hurts | Fix |
|---|---|---|
| Everyone reviews everything | Long cycles, diluted accountability | Domain-based reviewers by risk tier |
| One generic approval action | Signature meaning is unclear | Separate authored, reviewed, approved meanings |
| Comments handled in email | No attributable, complete record | Log comments and dispositions in the workflow |
| Traceability kept in a spreadsheet | Drifts from the real documents | Generate it live from linked identifiers |
| Audit trail reviewed only before inspections | Problems found late | Periodic, risk-based exception review |
| No path for revisions | Full re-review for small changes | Delta-scoped review with impact assessment |

## Our perspective: where agents fit and where they do not

We build validation software, so we see the same pattern across regulated teams. The slowest part of a review is rarely the thinking. It is the preparation: finding the right version, checking identifiers, reconciling comments, assembling evidence, and chasing signatures. That is a quiet tax on every validation cycle, and it grows precisely when audit pressure rises, producing the fire drill before an audit.

Our view is that automation should take over the preparation and the checking, and leave the judgment to people. In Qualitum, agents draft validation documents in your templates, re-check each draft, and every record is ALCOA+ checked at write-time and again at review-time. A reviewer opens a document that has already passed those checks, so their attention goes to the questions only a qualified person can answer: is this risk assessment sound, are these acceptance criteria meaningful?

![Our perspective: where agents fit and where they do not — overview diagram](https://media.babylovegrowth.ai/blog-images/organization-48457/1792577233336_Our-perspective-where-agents-fit-and-where-they-do-not-overview-diagram.jpeg)

The signature stays human. We do not think a regulator should be asked to accept an automated approval, and we do not design for one. We also deploy privately inside the customer's infrastructure, so review content and audit trails stay under the customer's control.

If you take one design principle from this article, make it this: let the workflow enforce the rules so reviewers do not have to remember them.

> *— Matt*

## Where Qualitum fits

If your review cycles are slowed by manual authoring and evidence assembly, the [Validate·AI and Operate·AI platform](https://qualitum.ai/platform/) is built for exactly this: agent-authored validation documents, a live traceability matrix, deviation and CAPA handling, and integrations with existing quality management systems. Teams that want to see it on their own documents can start with a [paid pilot](https://qualitum.ai/). For the authoring side, our article on [automated validation documents under FDA CSA](https://blog.qualitum.ai/automated-validation-documents) shows what audit-ready output looks like.

## A starting checklist

Use this list to audit an existing workflow or scope a new one:

1. Have you listed every document type and the decision each supports?
2. Are documents tiered by risk, with a route for each tier?
3. Does each reviewer have a written domain, and are out-of-domain comments advisory?
4. Are review and approval separate steps with distinct signature meanings?
5. Is every comment, edit and status change captured with user, time and version?
6. Can anyone edit a document in review without restarting the affected steps?
7. Is the traceability matrix generated from live links rather than maintained by hand?
8. Is there a defined exception report for audit trail review, and who owns it?
9. Has the workflow been tested with negative scenarios and the results recorded?
10. Is there a lighter, delta-based path for revisions and a schedule for periodic review?

## FAQ

### How many reviewers should a validation document have?

As few as the decision requires. Name the reviewers whose domain the document touches, typically technical, system owner and QA, and add others only when the risk justifies it. Extra reviewers lengthen the cycle without improving the evidence.

### Should reviews run in parallel or in sequence?

Use parallel review for independent domains and sequential approval for sign-off. Move to sequential review earlier only when one reviewer's work depends on another's, such as QA needing confirmed technical accuracy first.

### Does the review workflow itself need to be validated?

If it is software that creates, stores or signs GxP records, yes, in proportion to its risk. Test the controls that matter: role enforcement, version locking, audit trail integrity and signature manifestation. Include negative tests and record the results.

### Can AI agents approve validation documents?

We do not recommend it. Agents can draft, check and route documents, but a named, accountable person should provide the review and approval signature. That keeps the record attributable and the accountability clear for inspectors.

## Sources

- [FDA: Computer Software Assurance for Production and Quality Management System Software](https://www.fda.gov/media/188844/download)
- [MHRA: GxP data integrity guidance](https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/687246/MHRA_GxP_data_integrity_guide_March_edited_Final.pdf)
- [Microsoft Learn: Get started with Power Automate approvals](https://learn.microsoft.com/en-us/power-automate/get-started-approvals)
- [Envigilance: 21 CFR Part 11 electronic records guide](https://envigilance.com/compliance/21-cfr-part-11/)
- [Apaya: Content approval workflow](https://apaya.com/blog/content-approval-workflow)
- [Analytics Engineering in Regulated Environments](https://sakaradigital.com/blog/analytics-engineering-regulated-environments-dbt-validation/)
- [MedDeviceGuide: EDC validation, Part 11 and audit trail data integrity](https://meddeviceguide.com/blog/edc-validation-medical-device-clinical-trials-part-11-audit-trail-data-integrity-guide)
- [GCP Blog: ALCOA and ALCOA+ data integrity in clinical trials](https://gcpblog.org/alcoa-and-alcoa-data-integrity-in-clinical-trials/)
- [Powerfabric: GAMP 5 pharma automation validation guide](https://powerfabric.org/standards/gamp-5)

## Recommended

- [70% Faster Protocol Authoring: Checklist for Validation Teams](https://blog.qualitum.ai/protocol-authoring-guidelines)
- [Inspector Ready Validation Change Control: 6 Steps for QA Leads](https://blog.qualitum.ai/validation-change-control)
- [7 Inspection Ready CSV Best Practices for Validation Managers](https://blog.qualitum.ai/csv-best-practices)
- [Paperless Validation: A Practical Guide for QA Leaders](https://blog.qualitum.ai/paperless-validation)

## FAQ
### How many reviewers should a validation document have?
As few as the decision requires. Name the reviewers whose domain the document touches, typically technical, system owner and QA, and add others only when the risk justifies it. Extra reviewers lengthen the cycle without improving the evidence.

### Should reviews run in parallel or in sequence?
Use parallel review for independent domains and sequential approval for sign-off. Move to sequential review earlier only when one reviewer's work depends on another's, such as QA needing confirmed technical accuracy first.

### Does the review workflow itself need to be validated?
If it is software that creates, stores or signs GxP records, yes, in proportion to its risk. Test the controls that matter: role enforcement, version locking, audit trail integrity and signature manifestation. Include negative tests and record the results.

### Can AI agents approve validation documents?
We do not recommend it. Agents can draft, check and route documents, but a named, accountable person should provide the review and approval signature. That keeps the record attributable and the accountability clear for inspectors.
